NDA 217225 · Astellas
Izervay
Avacincaptad Pegol Sodium · Intravitreal
NovelBreakthrough therapyPriority reviewCDER novel approval, Aug 4, 2023: To treat geographic atrophy secondary to age-related macular degeneration
Last checked: Nov 20, 2026Latest source record: Feb 27, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Aug 4, 2023
Approved uses
2
Original approval plus efficacy supplements
Registered trials
13
3 Phase 3, 1 recruiting
FAERS reports
352
141 serious, 5 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 3, 2026.
IZERVAY ® is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). IZERVAY is a complement inhibitor indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) ( 1 ).
Mechanism: Avacincaptad pegol is an RNA aptamer, a PEGylated oligonucleotide that binds to and inhibits complement protein C5. By inhibiting C5, avacincaptad pegol may prevent its cleavage to C5a and C5b thus decreasing membrane attack complex (MAC) formation.
Therapeutic areas: Ophthalmology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 12, 2025 Supplement 1 · Efficacy LetterLabel
- Aug 4, 2023 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyLetterLabelReview
1 products under this application
- IZERVAY · AVACINCAPTAD PEGOL SODIUM EQ 2MG BASE/0.1ML (EQ 2MG BASE/0.1ML) · SOLUTION, INTRAVITREAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Avacincaptad Pegol" as an intervention, any sponsor and status, largest first.
- A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)Pivotal-lookingCompleted
IVERIC bio, Inc.Industry
NCT04435366 · 448 participants · Start Jun 22, 2020 · Primary completion Jul 25, 2022
Drug: Avacincaptad Pegol; Sham · For: Geographic Atrophy; Macular Degeneration
Sites: Beverly Hills, California; Campbell, California; Fresno, California · 205 sites in all
- Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMDPivotal-lookingRecruiting
ONL TherapeuticsIndustry
NCT06659445 · 324 participants (planned) · Start Oct 28, 2025 · Primary completion Nov 2028
Drug: ONL1204 Opthalmic solution; Avacincaptad Pegol intravitreal solution · For: Geographic Atrophy (GA); Age - Related Macular Degeneration (AMD)
Sites: Gilbert, Arizona; Phoenix, Arizona; Bakersfield, California · 120 sites in all
- Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular DegenerationPivotal-lookingCompleted
IVERIC bio, Inc.Industry
NCT02686658 · 286 participants · Start Dec 15, 2015 · Primary completion Sep 26, 2019
Drug: Avacincaptad Pegol · For: Geographic Atrophy; Dry Age-Related Macular Degeneration
Sites: Phoenix, Arizona; Tucson, Arizona; Campbell, California · 78 sites in all
- Avacincaptad Pegol Open-Label Extension for Patients With Geographic AtrophyPivotal-lookingCompleted
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT05536297 · 278 participants · Start Sep 26, 2022 · Primary completion Apr 10, 2025
Drug: avacincaptad pegol · For: Geographic Atrophy; Age-Related Macular Degeneration
Sites: Campbell, California; Fresno, California; Fullerton, California · 117 sites in all
- Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)Pivotal-lookingCompleted
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT03364153 · 121 participants · Start Jan 12, 2018 · Primary completion Mar 31, 2025
Drug: avacincaptad pegol; Sham · For: Stargardt's Macular Dystrophy
Sites: Phoenix, Arizona; Los Angeles, California; Gainesville, Florida · 41 sites in all
Ophthotech CorporationIndustry
NCT03362190 · 64 participants · Start Oct 11, 2017 · Primary completion Oct 18, 2018
Drug: Avacincaptad Pegol; Lucentis · For: Neovascular Age-related Macular Degeneration
Sites: Phoenix, Arizona; Tucson, Arizona; Beverly Hills, California · 28 sites in all
Ophthotech CorporationIndustry
NCT00709527 · 60 participants · Start Oct 16, 2008 · Primary completion Dec 30, 2009
Drug: Avacincaptad Pegol · For: Neovascular Age-Related Macular Degeneration
Sites: New York, New York
Ophthotech CorporationIndustry
NCT00950638 · 47 participants · Start Jul 16, 2009 · Primary completion Mar 24, 2011
Drug: Avacincaptad Pegol · For: Dry Age-Related Macular Degeneration
Sites: New York, New York
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- visual impairment26
- intercepted product preparation error25
- eye pain24
- no adverse event24
- needle issue23
- off label use22
- vision blurred22
- syringe issue18
- endophthalmitis16
- product temperature excursion issue16
- choroidal neovascularisation15
- intraocular pressure increased15
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2023 | 5 |
| 2024 | 110 |
| 2025 | 114 |
| 2026 | 123 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Izervay (Avacincaptad PEGol Sodium/PF)
2024 spending
$3.9M
Beneficiaries
343
1,353 claims
Per beneficiary
$11,413
$20,900.99 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $216,001 |
| 2024 | $3,914,756 |
Part B: Izervay (Avacincaptad Pegol Sodium/PF) · HCPCS J2782
2024 spending
$190M
Beneficiaries
18,308
73,172 claims
Per beneficiary
$10,398
2024 ASP limit $110.43 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $190,365,233 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial.
Jaffe GJ, Westby K, Csaky KG, et al. · Ophthalmology 2021 · Clinical Trial, Phase II, Clinical Trial, Phase III
- Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial.
Patel SS, Lally DR, Hsu J, et al. · Eye (Lond) 2023 · Randomized Controlled Trial, Clinical Trial, Phase II
- The effect of complement C3 or C5 inhibition on geographic atrophy secondary to age-related macular degeneration: A living systematic review and meta-analysis.
Garg A, Nanji K, Tai F, et al. · Surv Ophthalmol 2024 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Vision Loss Reduction with Avacincaptad Pegol for Geographic Atrophy: A 12-Month Post Hoc Analysis of the GATHER1 and GATHER2 Trials.
Danzig CJ, Khanani AM, Kaiser PK, et al. · Ophthalmol Retina 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Correlation Between Blue Fundus Autofluorescence and SD-OCT Measurements of Geographic Atrophy in Dry Age-Related Macular Degeneration.
Ehlers JP, McConville C, Yordi S, et al. · Am J Ophthalmol 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Avacincaptad Pegol for Geographic Atrophy Secondary to Age-Related Macular Degeneration: Two-Year Efficacy and Safety Results from the GATHER2 Phase 3 Trial.
Khanani AM, Danzig CJ, Heier JS, et al. · Ophthalmology 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
Sponsor: Astellas
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.